Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
simvastatin + fenebrutinib
- Development stage
- Phase 1
- Lead developer
- Genentech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Simvastatin + fenebrutinib is a combination of two small molecule drugs. Simvastatin is an HMG-CoA reductase inhibitor (statin) used to lower cholesterol and reduce the risk of cardiovascular events by inhibiting the enzyme responsible for cholesterol synthesis in the liver[1][2]. Fenebrutinib (GDC-0853) is a selective, reversible, non-covalent inhibitor of Bruton's tyrosine kinase (BTK), developed for autoimmune and inflammatory diseases as well as certain hematologic malignancies[5][6][8]. The combination has been studied in drug-drug interaction trials but is not an approved therapeutic regimen.
- Other names
- simvastatinfenebrutinib
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on simvastatin + fenebrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on simvastatin + fenebrutinib.